Dr. Lukasz Kedzierski

Prof. Lukasz Kedzierski

Monash University, Australia



2002 Ph.D., Monash University, Microbiology

1996 B.Sc., Monash University, Microbiology

Publications (Selected)

  1. Kedzierski, L., Black, C.G. and Coppel, R.L. (2000). Characterisation of the merozoite surface protein 4/5 of Plasmodium berghei and Plasmodium yoelii. Mol Biochem Parasitol 105: 137-147.
  2. Kedzierski, L., Black, C.G. and Coppel, R.L. (2000). Immunisation with recombinant Plasmodium yoelii merozoite surface protein 4/5 protect mice against lethal challenge. Infect Immun 68(10): 6034-6037.
  3. Kedzierski, L., Black, C.G., Goschnick, M.W., Stowers, A.W., Kaslow, D.C. and Coppel, R.L. (2001) Comparison of the protective efficacy of yeast-derived and Escherichia coli-derived recombinant merozoite surface protein 4/5 against lethal challenge by Plasmodium yoelii. Vaccine 19: 4661-4668.
  4. Kedzierski, L., Escalante, A.A., Isea, R., Black, C.G., Barnwell, J.W. and Coppel, R.L. (2002) Phylogenetic analysis of the genus Plasmodium based on the gene encoding adenylosuccinate lyase. Infect Genet Evol 1(4): 297-301.
  5. Kedzierski, L., Black, C.G., Goschnick, M.W., Stowers, A.W. and Coppel, R.L. (2002) Immunization with a combination of merozoite surface proteins 4/5 and 1 enhances protection against lethal challenge with Plasmodium yoelii. Infect Immun 70(12): 6606-6613.
  6. Wang, L., Kedzierski, L., Wesselingh, S.L. and Coppel, R.L. (2003) Oral immunization with a recombinant malaria protein induces conformational antibodies and protects mice against lethal malaria. Infect Immun 71(5): 2356-2364.
  7. Rainczuk, A., Smooker, P.M., Kedzierski, L., Black, C.G., Coppel, R.L. and Spithill, T.W. (2003) The protective efficacy of MSP4/5 against lethal Plasmodium chabaudi adami challenge is dependent on the type of DNA vaccine vector and vaccination protocol. Vaccine 21: 3030-3042.
  8. Kedzierski, L., Montgomery, J., Bullen, D., Curtis, J., Gardiner, E., Jimenez-Ruiz, A. and Handman, E. (2004) A leucine-rich repeat motif of Leishmania parasite surface antigen 2 binds to macrophages through the complement receptor 3. J Immunol 172: 4902-4906.
  9. Goschnick, M.W., Black, C.G., Kedzierski, L., Holder, A.A. and Coppel R.L. (2004) Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strain. Infect Immun 72(10): 5840-5849.
  10. Kedzierski, L., Montgomery, J., Curtis, J. and Handman, E. (2004) Leucine-rich repeats in host-pathogen interactions. Arch Immunol Ther Exp 52: 104-112.
  11. Wang, L., Kedzierski, L., Schofield, L. and Coppel, R.L. (2005) Influence of glycophosphatidylinositol anchorage on the efficacy of DNA vaccines encoding Plasmodium yoelii merozoite surface protein 4/5. Vaccine 23: 4120-4127.
  12. Davis, A.J. and Kedzierski, L. (2005) Recent advances in antileishmanial drug development. Curr Opin Investig Drugs 6(2): 163-169.
  13. Kedzierski, L., Malby, R.L., Smith, B.J., Perugini, M.A., Hodder, A.N., Colman, P.M. and Handman, E. (2006) Structure of Leishmania mexicana phosphomannomutase highlights similarities with human isoforms. J Mol Biol 363: 215-227.
  14. Kedzierski, L., Zhu, Y. and Handman, E. (2006) Leishmania vaccines: progress and problems. Parasitology 133: Suppl S87-112.
  15. Kedzierski, L., Curtis, J.M., Kaminska, M., Jodynis-Liebert, J. and Murias, M. (2007) In vitro antileishmanial activity of resveratrol and its hydroxylated analogues against Leishmania major promastigotes and amastigotes. Parasitol Res 102: 91-97.
  16. Kedzierski, L., Curtis, J.M., Doherty, P.C., Handman, E. and Kedzierska, K. (2008) Decreased IL-10 and IL-13 production and increased CD44hi T cell recruitment contribute to Leishmania major immunity induced by non-persistent parasites. Eur J Immunol, 38: 3090-3100.
  17. Handman, E., Kedzierski, L., Uboldi, A.U. and Goding, J.W. (2008) Fishing for Anti-Leishmania Drugs: Principles and Problems in Drug Targets in Kinetoplastid Parasites, Majumder, Hemanta K. (Ed.), Springer Science+Business Media, LLC; Landes Bioscience, ISBN: 978-0-387-77569-2, Series: Advances in Experimental Medicine and Biology, Vol. 625, pg. 48-60.
  18. Kedzierski, L., Curtis, J.M. and Kedzierska, K. (2009) Early CD44hiCD4+ and CD44hiCD8+ T cell numbers and the absence of mannose-rich glycoconjugates determine the protective outcome of antileishmanial immunity. Parasitology 136(8): 833-840.
  19. Branson, K.M, Mertens, H.D.T. Swarbrick, J.D., Fletcher, J.I., Kedzierski, L., Gayler, K.R., Gooley, P.R. and Smith, B.J. (2009) Discovery of inhibitors of lupin Ap4A-hydrolase by virtual screening. Biochemistry 48: 7614-7620.
  20. Kedzierski, L., Sakthianandeswaren, A. Curtis, J.M., Andrews, P.C., Junk, P.C. and Kedzierska, K. (2009) Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr Med Chem, 16(5): 599-614.
  21. Kedzierska, K., Valkenburg, S., Guilloneau, C., Hubert, F.X., Cukalac, T., Curtis, J.M., Stambas, J., Scott, H., Kedzierski, L., Venturi, V. and Davenport, P.D. (2010) Diversity and clonotypic composition of influenza specific CD8+ TCR repertoires remain unaltered in the absence of Aire. Eur J Immunol 40: 849-858.
  22. Lackovic, K., Parisot, J.P., Sleebs, N., Baell, J.B., Debien, L., Watson, K.G., Handman, E., Street, I.P. and Kedzierski, L. (2010) Inhibitors of Leishmania GDP-mannose pyrophosphorylase identified by high-throughput screening for small molecule chemical library. Antimicrob Agents Chemother 54(5): 1712-1719.
  23. Sakthianandeswaren, A., Curtis, J.M., Elso, C., Kumar, B., Baldwin, T.M., Lopaticki, S., Kedzierski, L., Kile, B.T., Kallies, A., Smyth, G.K., Foote, S.J. and Handman, E. (2010) Fine mapping of Leishmania major susceptibility locus lmr2: evidence for a role for Fli1 in disease and wound healing. Infect Immun 78(6): 2634-2744.
  24. Kuang, Z., Lewis, R.S., Curtis, J.M., Zhan, Y., Saunders, B., Babon, J.J., Kolesnik, T.B., Low, A., Masters, S.L., Willson, T.A., Kedzierski, L., Yao, S., Handman, E., Norton, R.S. and Nicholson, S.E. (2010) The SPRY domain-containing SOCS box proteins, SPSB1 and SPSB2, target inducible nitric oxide synthase (iNOS) for ubiquitination and proteasomal degradation. J Cell Biol 190(1): 129-141.
  25. Gras, S.*, Kedzierski, L.*, Valkenburg, S.A.*, Laurie, K., Denholm, J., Richards, M., Kelso, A., Doherty, P.C., Turner, S.J., Rossjohn, J. and Kedzierska, K. (2010) Cross-reactive CD8+ T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses. Proc Nat Acad Sci USA 107(28): 12599-12604. (* = equal contribution).
  26. Kedzierski, L. (2010) Leishmaniasis vaccine: Where are we today? J Glob Infect Dis 2(2): 177-18.
  27. Andrews, P.C., Frank, R. Junk, P.C., Kedzierski, L., Kumar, I. and MacLellan, J.G. (2011) Antileishmanial activity of homo- and heteroleptic Bismuth (III) carboxylates. J Inorg Biochem 105: 454-461.
  28. Gorman, M.A., Uboldi, A.D., Walsh, P.J., Tan, K.S., Hansen, G., Huyton, T., Ji, H., Curtis, J., Kedzierski, L., Papenfuss, A.T., Dogovski, C., Perugini, M.A., Simpson, R.J., Handman, E. and Parker, M.W. (2011) Crystal structure of the Leishmania major MIX protein: a scaffold protein that mediates protein-protein interactions. Protein Sci 20: 1060-1068.
  29. The Working Group on Research Priorities for Development of Leishmaniasis Vaccines (including Kedzierski, L.) Costa, C.H., Peters, N.C., Maruyama, S.R., de Brito Jr., E.C. and de Miranda Santos, I.K. (2011) Vaccines for the Leishmaniases: Proposals for a Research Agenda. PLoS Negl Trop Dis 5(3): e943, doi:10.1371/journal.pntd.0000943.

Last Updated: August, 2012